ConductScience.org, home

Paper19879639

Current state of biomarker development for clinical application in epithelial ovarian cancer.

Moore RG and 2 others. Gynecol Oncol, 2010. Cited by 73 papers, by iCite.

Cite this record

ConductScience Library. Current state of biomarker development for clinical application in epithelial ovarian cancer. Papers, record 19879639. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19879639

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Current state of biomarker development for clinical application in epithelial ovarian cancer.
PubMed
Journal
Gynecol Oncol
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
73
iCite
Relative citation ratio, by iCite
1.95
iCite
Revised in PubMed
2025-05-29
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moore RGRichard G
2MacLaughlan SShannon
3Bast RC JrRobert C

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biomarkers, TumorMajor topic
Ovarian NeoplasmsMajor topic
CA-125 Antigen
Female
Humans
Mass Screening
Risk Assessment

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016672NCI NIH HHSUnited StatesP30CA016672PubMed and NIHNIH RePORTER
P50 CA083639NCI NIH HHSUnited StatesP50CA083639PubMed and NIHNIH RePORTER
R01 CA136491NCI NIH HHSUnited StatesR01CA136491PubMed and NIHNIH RePORTER
P50 CA83639NCI NIH HHSUnited StatesP50CA083639PubMed and NIHNIH RePORTER

Download CSV of grants

References63

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119423517Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.Cancer Epidemiol Biomarkers Prev2009https://conductscience.org/library/papers/19423517PubMed
28166218The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.Am J Obstet Gynecol1994https://conductscience.org/library/papers/8166218PubMed
319337252Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.Br J Cancer2009https://conductscience.org/library/papers/19337252PubMed
417420977Predictors of comprehensive surgical treatment in patients with ovarian cancer.Cancer2007https://conductscience.org/library/papers/17420977PubMed
58805927Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.Ann Oncol1996https://conductscience.org/library/papers/8805927PubMed
617954908Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17954908PubMed
78634992Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.Cancer1995https://conductscience.org/library/papers/8634992PubMed
817473066Total inhibin is a potential serum marker for epithelial ovarian cancer.J Clin Endocrinol Metab2007https://conductscience.org/library/papers/17473066PubMed
916394300Intraperitoneal cisplatin and paclitaxel in ovarian cancer.N Engl J Med2006https://conductscience.org/library/papers/16394300PubMed
1012743136Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.J Clin Oncol2003https://conductscience.org/library/papers/12743136PubMed
1119282241
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Lancet Oncol2009https://conductscience.org/library/papers/19282241PubMed
128760716Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.Br J Obstet Gynaecol1996https://conductscience.org/library/papers/8760716PubMed
1311198956Epithelial ovarian cancer: prevention, diagnosis, and treatment.CA Cancer J Clin1999https://conductscience.org/library/papers/11198956PubMed
1412468197ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer.Obstet Gynecol2002https://conductscience.org/library/papers/12468197PubMed
1515781627Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.Cancer Res2005https://conductscience.org/library/papers/15781627PubMed
1618604735Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study.Pathology2008https://conductscience.org/library/papers/18604735PubMed
177028788Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest1981https://conductscience.org/library/papers/7028788PubMed
182227570
Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
Gynecol Oncol1990https://conductscience.org/library/papers/2227570PubMed
192418395Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.Obstet Gynecol1986https://conductscience.org/library/papers/2418395PubMed
2019240799Development and preliminary evaluation of a multivariate index assay for ovarian cancer.PLoS One2009https://conductscience.org/library/papers/19240799PubMed

See all 63 referencesDownload CSV of references

Cited by33

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 73 citations.

PMIDTitleJournalYearIn PapersSource
42597227Integration of serological markers with O-RADS ultrasound risk stratification achieves high diagnostic accuracy for early ovarian cancer: development and validation of an interpretable model.Am J Cancer Res2026https://conductscience.org/library/papers/42597227PubMed
41515549Diagnostic Value of CA-125 and Other Tumor Biomarkers in Children with Suspected Malignancy: A Retrospective Cohort Study.Diagnostics (Basel)2025https://conductscience.org/library/papers/41515549PubMed
40598419Peritoneal cavity-derived small extracellular vesicles from aged tumor-naïve hosts promote ovarian cancer adhesion and invasion.Cell Commun Signal2025https://conductscience.org/library/papers/40598419PubMed
37884576Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer.Sci Rep2023https://conductscience.org/library/papers/37884576PubMed
36719438A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer.Anal Bioanal Chem2023https://conductscience.org/library/papers/36719438PubMed
36713666
Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms.
Front Surg2022https://conductscience.org/library/papers/36713666PubMed
36082820Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome.Int J Oncol2022https://conductscience.org/library/papers/36082820PubMed
32393810miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis.Cell Death Dis2020https://conductscience.org/library/papers/32393810PubMed
31608277Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.Front Cell Dev Biol2019https://conductscience.org/library/papers/31608277PubMed
31122127Long noncoding RNA MAGI1-IT1 promoted invasion and metastasis of epithelial ovarian cancer via the miR-200a/ZEB axis.Cell Cycle2019https://conductscience.org/library/papers/31122127PubMed
30516730Can Presurgical Ultrasound Predict Survival in Women With Ovarian Masses?Ultrasound Q2019https://conductscience.org/library/papers/30516730PubMed
30024542A preliminary study: The sequential use of the risk malignancy index and contrast-enhanced ultrasonography in differential diagnosis of adnexal masses.Medicine (Baltimore)2018https://conductscience.org/library/papers/30024542PubMed
28927094Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy.Oncol Lett2017https://conductscience.org/library/papers/28927094PubMed
28452952Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials.Diagnostics (Basel)2017https://conductscience.org/library/papers/28452952PubMed
28202518Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.Cancer Res2017https://conductscience.org/library/papers/28202518PubMed
28008951The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis.Sci Rep2016https://conductscience.org/library/papers/28008951PubMed
27997533Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.PLoS Med2016https://conductscience.org/library/papers/27997533PubMed
27802199Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma.Cancer Biomark2016https://conductscience.org/library/papers/27802199PubMed
26005273Comparison of specific ovarian tumor markers by elecsys analyzer 2010.Acta Inform Med2015https://conductscience.org/library/papers/26005273PubMed
25225597In 2014, can we do better than CA125 in the early detection of ovarian cancer?World J Biol Chem2014https://conductscience.org/library/papers/25225597PubMed

See all 33 cited byDownload CSV of cited by

Genes15

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19879639

GET https://conductscience.org/api/papers/v1/19879639/references?page=2